[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ct83-gene":3},{"name":4,"total":5,"trials":6},"CT83 Gene",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07652242","First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )",[11],"Phase 1","RECRUITING","2026-08-03T03:33:28.152084Z","2026-06-17T19:21:16.686289Z"]